VVD-101

Cady, Roger, M.D. · Phase 2 active Small molecule

At a glance

Generic name	VVD-101
Also known as	sumatriptan succinate 12.5 mg & acetylsalicylic acid 325 mg
Sponsor	Cady, Roger, M.D.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VVD-101 CI brief — competitive landscape report
VVD-101 updates RSS · CI watch RSS
Cady, Roger, M.D. portfolio CI